首页 > 最新文献

Przegla̜d Gastroenterologiczny最新文献

英文 中文
Assessment of the activity of the immune system in patients with inflammatory bowel diseases and asymptomatic COVID-19. 评估炎症性肠病患者和无症状 COVID-19 患者的免疫系统活性。
IF 1.3 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2023-01-19 DOI: 10.5114/pg.2023.124281
Michał Łodyga, Katarzyna Maciejewska, Kamila Stawczyk-Eder, Piotr Eder, Agnieszka Dobrowolska, Maria Wiśniewska-Jarosińska, Anita Gąsiorowska, Małgorzata Cicha, Grażyna Rydzewska

Introduction: Although the phenomenon of cytokine storm is well described in patients with severe COVID-19, little is known about the role of the immune system in asymptomatic patients, especially in the group with autoimmune diseases, such as inflammatory bowel disease (IBD).

Aim: To assess the stimulation of the immune system expressed through the production of cytokines in IBD patients with asymptomatic COVID-19.

Material and methods: This is a multi-centre, prospective study in which the concentration of many cytokines (IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL- 15, IL-17, IL-23, IFN-γ, TNF-α, TNF-β) was assessed in patients with IBD and asymptomatic SARS-CoV-2 infection diagnosed by serological tests.

Results: In the group of patients with a recent SARS-CoV-2 infection, defined as positive antibodies in the IgA + IgM class, a higher percentage of patients with the presence of interleukin (IL) 2 (IL-2) was found. No association with other cytokines or effects of IBD activity or treatment was found. However, the effect of the applied treatment on the concentration of some cytokines was found: a negative association of infliximab, vedolizumab, and prednisone with IL-2, a positive correlation of steroids, thiopurines with IL-10, and in the case of tumor necrosis factor-α (TNF-α), negative with infliximab, and positive with vedolizumab.

Conclusions: The increased concentration of IL-2 may result from its regulatory role in inhibiting excessive activation of the immune system; however, considering the studies of patients with severe COVID-19, its role in the initial phase of SARS-CoV-2 infection requires further research.

导言:尽管细胞因子风暴现象在重症COVID-19患者中得到了很好的描述,但人们对免疫系统在无症状患者中的作用知之甚少,尤其是在患有自身免疫性疾病的群体中,如炎症性肠病(IBD):这是一项多中心前瞻性研究,评估了通过血清学检测确诊的 IBD 患者和无症状 SARS-CoV-2 感染者体内多种细胞因子(IL-1a、IL-1b、IL-2、IL-4、IL-5、IL-6、IL-8、IL-10、IL-12、IL-13、IL-15、IL-17、IL-23、IFN-γ、TNF-α、TNF-β)的浓度:在近期感染过 SARS-CoV-2 的患者组(定义为 IgA + IgM 类抗体阳性)中,发现白细胞介素(IL)2(IL-2)阳性的患者比例较高。没有发现与其他细胞因子或 IBD 活动或治疗的影响有关。然而,研究发现了应用治疗对某些细胞因子浓度的影响:英夫利昔单抗、维多珠单抗和泼尼松与 IL-2 呈负相关,类固醇、硫嘌呤与 IL-10 呈正相关,而肿瘤坏死因子-α(TNF-α)与英夫利昔单抗呈负相关,与维多珠单抗呈正相关:IL-2浓度的增加可能是由于它在抑制免疫系统过度激活方面的调节作用;然而,考虑到对严重COVID-19患者的研究,它在SARS-CoV-2感染初期的作用还需要进一步研究。
{"title":"Assessment of the activity of the immune system in patients with inflammatory bowel diseases and asymptomatic COVID-19.","authors":"Michał Łodyga, Katarzyna Maciejewska, Kamila Stawczyk-Eder, Piotr Eder, Agnieszka Dobrowolska, Maria Wiśniewska-Jarosińska, Anita Gąsiorowska, Małgorzata Cicha, Grażyna Rydzewska","doi":"10.5114/pg.2023.124281","DOIUrl":"10.5114/pg.2023.124281","url":null,"abstract":"<p><strong>Introduction: </strong>Although the phenomenon of cytokine storm is well described in patients with severe COVID-19, little is known about the role of the immune system in asymptomatic patients, especially in the group with autoimmune diseases, such as inflammatory bowel disease (IBD).</p><p><strong>Aim: </strong>To assess the stimulation of the immune system expressed through the production of cytokines in IBD patients with asymptomatic COVID-19.</p><p><strong>Material and methods: </strong>This is a multi-centre, prospective study in which the concentration of many cytokines (IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL- 15, IL-17, IL-23, IFN-γ, TNF-α, TNF-β) was assessed in patients with IBD and asymptomatic SARS-CoV-2 infection diagnosed by serological tests.</p><p><strong>Results: </strong>In the group of patients with a recent SARS-CoV-2 infection, defined as positive antibodies in the IgA + IgM class, a higher percentage of patients with the presence of interleukin (IL) 2 (IL-2) was found. No association with other cytokines or effects of IBD activity or treatment was found. However, the effect of the applied treatment on the concentration of some cytokines was found: a negative association of infliximab, vedolizumab, and prednisone with IL-2, a positive correlation of steroids, thiopurines with IL-10, and in the case of tumor necrosis factor-α (TNF-α), negative with infliximab, and positive with vedolizumab.</p><p><strong>Conclusions: </strong>The increased concentration of IL-2 may result from its regulatory role in inhibiting excessive activation of the immune system; however, considering the studies of patients with severe COVID-19, its role in the initial phase of SARS-CoV-2 infection requires further research.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"1 1","pages":"46-53"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70474965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor in the treatment of gastroesophageal reflux disease. 伊托必利作为质子泵抑制剂的附加疗法治疗胃食管反流病的有效性和安全性。
IF 1.3 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2023-12-28 DOI: 10.5114/pg.2023.133915
Dorota Wasko-Czopnik, Benita Wiatrak

Introduction: The primary objective was to demonstrate the efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor (PPI) in the treatment of gastroesophageal reflux disease.

Aim: Reflux disease affects the largest percentage of the population worldwide, symptoms overlap with many other conditions which hamper diagnostic and therapy presenting challenges in treating patients and prompting an intensive search for new, more effective therapeutic regimens.

Material and methods: A retrospective study was undertaken with 140 enrolled patients with reflux disease, confirmed by 24-hour pH impedance previously treated with PPIs without any significant improvement. Itopride was added to the PPI therapy in a dose of 150 mg/day, after which the severity of reflux disease symptoms was reassessed.

Results: The greatest improvement after the combined treatment (p < 0.001) was experienced in the context of heartburn, nausea and laryngopharyngeal symptoms. There was also a high percentage of statistically significant (p < 0.01) improvement in burning in the oesophagus and stomach and regarding postprandial fullness, gastric retention and swallowing disorders. No adverse effects were noted.

Conclusions: The presented study clearly demonstrates that in patients ineffectively treated with PPIs, the addition of itopride to the therapy for 8 weeks without changing the PPI dose, significantly improves the efficacy of treatment of reflux disease and thus shortens the need for medication usage and reduces the costs of therapy, potential side effects of PPI, improves the patient's quality of life and decreases the frequency of medical appointments.

简介:主要目的是证明伊托必利作为质子泵抑制剂(PPI)的附加疗法治疗胃食管反流病的有效性和安全性:目的:反流病在全球人口中所占比例最大,其症状与许多其他疾病重叠,妨碍了诊断和治疗,给患者的治疗带来了挑战,促使人们加紧寻找新的、更有效的治疗方案:我们对 140 名入选的反流病患者进行了一项回顾性研究,这些患者经 24 小时 pH 值阻抗确认患有反流病,此前曾接受过 PPIs 治疗,但病情未得到明显改善。伊托必利被添加到 PPI 治疗中,剂量为 150 毫克/天,之后重新评估反流病症状的严重程度:结果:联合治疗后,胃灼热、恶心和喉咽部症状得到了最大程度的改善(p < 0.001)。此外,食道和胃部烧灼感、餐后饱胀、胃潴留和吞咽障碍等症状也有很大比例的改善,具有显著的统计学意义(p < 0.01)。没有发现任何不良反应:本研究清楚地表明,对于使用 PPIs 治疗无效的患者,在不改变 PPI 剂量的情况下,在 8 周的治疗中添加伊托必利,可显著提高反流病的疗效,从而缩短用药时间,降低治疗成本和 PPI 的潜在副作用,改善患者的生活质量,减少就诊次数。
{"title":"The efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor in the treatment of gastroesophageal reflux disease.","authors":"Dorota Wasko-Czopnik, Benita Wiatrak","doi":"10.5114/pg.2023.133915","DOIUrl":"https://doi.org/10.5114/pg.2023.133915","url":null,"abstract":"<p><strong>Introduction: </strong>The primary objective was to demonstrate the efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor (PPI) in the treatment of gastroesophageal reflux disease.</p><p><strong>Aim: </strong>Reflux disease affects the largest percentage of the population worldwide, symptoms overlap with many other conditions which hamper diagnostic and therapy presenting challenges in treating patients and prompting an intensive search for new, more effective therapeutic regimens.</p><p><strong>Material and methods: </strong>A retrospective study was undertaken with 140 enrolled patients with reflux disease, confirmed by 24-hour pH impedance previously treated with PPIs without any significant improvement. Itopride was added to the PPI therapy in a dose of 150 mg/day, after which the severity of reflux disease symptoms was reassessed.</p><p><strong>Results: </strong>The greatest improvement after the combined treatment (<i>p</i> < 0.001) was experienced in the context of heartburn, nausea and laryngopharyngeal symptoms. There was also a high percentage of statistically significant (<i>p</i> < 0.01) improvement in burning in the oesophagus and stomach and regarding postprandial fullness, gastric retention and swallowing disorders. No adverse effects were noted.</p><p><strong>Conclusions: </strong>The presented study clearly demonstrates that in patients ineffectively treated with PPIs, the addition of itopride to the therapy for 8 weeks without changing the PPI dose, significantly improves the efficacy of treatment of reflux disease and thus shortens the need for medication usage and reduces the costs of therapy, potential side effects of PPI, improves the patient's quality of life and decreases the frequency of medical appointments.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 1","pages":"60-66"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic value of apparent diffusion coefficient of psoas muscles for evaluating complications in patients with Crohn's disease. 腰肌表观弥散系数对评估克罗恩病患者并发症的诊断价值。
IF 1.3 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-01-22 DOI: 10.5114/pg.2024.134519
Bohdan Melekh, Felix Barajas Ordonez, Oksana Melekh, Wiebke Flintrop, Maciej Pech, Alexey Surov

Aim: To assess the association of the apparent diffusion coefficient (ADC) of the psoas muscles and psoas muscle index (PMI) with the activity and behaviour of Crohn's disease (CD).

Material and methods: This was a retrospective study of 88 CD patients who underwent magnetic resonance enterography. Patients were classified according to the Montreal Classification in uncomplicated (non-stricturing, non-penetrating, B1), and complicated (structuring [B2] and penetrating disease [B3]). At the level of the third lumbar vertebra, the ADC and PMI were estimated. CD activity was analysed using the Magnetic Resonance Index of Activity (MaRIA), and depending on its values patients were categorized as high or low activity. Additionally, the presence of creeping fat (CrF) was used to evaluate activity. ADC and PMI were using Student's t-test.

Results: Our study included 47 males and 41 females (mean age of 38.69 ±14.4 years). The ADC in uncomplicated (B1, n = 45) and complicated disease (B2 + B3, n = 43) were 1.11 ±0.19 and 1.03 ±0.10 (10-3*mm2/s), respectively, (p = 0.02). ADC was significantly lower in patients with stricturing disease than in patients without strictures (1.02 ±0.11 and 1.10 ±0.18 [10-3 mm2/s], respectively, p = 0.01). The group with non-penetrating disease showed higher PMI than those with penetrating disease (5.71 ±1.88 vs. 4.42 ±1.55 cm2/m2, respectively, p = 0.10). There was no significant difference in PMI and ADC between patients with low and high MaRIA or positive and negative CrF.

Conclusions: The ADC of the psoas muscles is significantly lower in CD patients with uncomplicated disease, particularly those with stricturing disease. Therefore, ADC can be considered as an imaging biomarker of myopathic changes in CD patients.

目的:评估腰肌表观弥散系数(ADC)和腰肌指数(PMI)与克罗恩病(CD)的活动和行为之间的关系:这是一项回顾性研究,研究对象是88名接受磁共振肠造影术的克罗恩病患者。根据蒙特利尔分类法,患者被分为非复杂性(非结构性、非穿透性,B1)和复杂性(结构性[B2]和穿透性疾病[B3])。在第三腰椎水平,对 ADC 和 PMI 进行了估算。采用磁共振活动指数(MaRIA)分析 CD 的活动性,并根据其数值将患者分为高活动性和低活动性两类。此外,蠕变脂肪(CrF)的存在也可用于评估活动度。ADC 和 PMI 采用学生 t 检验:我们的研究包括 47 名男性和 41 名女性(平均年龄为 38.69 ±14.4 岁)。无并发症(B1,n = 45)和并发症(B2 + B3,n = 43)的 ADC 分别为 1.11 ±0.19 和 1.03 ±0.10 (10-3*mm2/s),(p = 0.02)。狭窄性疾病患者的 ADC 明显低于非狭窄性疾病患者(分别为 1.02 ±0.11 和 1.10 ±0.18 [10-3 mm2/s],p = 0.01)。非穿透性疾病组的 PMI 比穿透性疾病组高(分别为 5.71 ±1.88 和 4.42 ±1.55 cm2/m2,P = 0.10)。低MaRIA和高MaRIA、CrF阳性和阴性患者的PMI和ADC没有明显差异:结论:腰肌ADC在无并发症的CD患者中明显较低,尤其是那些病情严格的患者。因此,ADC可被视为CD患者肌病变的影像生物标志物。
{"title":"Diagnostic value of apparent diffusion coefficient of psoas muscles for evaluating complications in patients with Crohn's disease.","authors":"Bohdan Melekh, Felix Barajas Ordonez, Oksana Melekh, Wiebke Flintrop, Maciej Pech, Alexey Surov","doi":"10.5114/pg.2024.134519","DOIUrl":"https://doi.org/10.5114/pg.2024.134519","url":null,"abstract":"<p><strong>Aim: </strong>To assess the association of the apparent diffusion coefficient (ADC) of the psoas muscles and psoas muscle index (PMI) with the activity and behaviour of Crohn's disease (CD).</p><p><strong>Material and methods: </strong>This was a retrospective study of 88 CD patients who underwent magnetic resonance enterography. Patients were classified according to the Montreal Classification in uncomplicated (non-stricturing, non-penetrating, B1), and complicated (structuring [B2] and penetrating disease [B3]). At the level of the third lumbar vertebra, the ADC and PMI were estimated. CD activity was analysed using the Magnetic Resonance Index of Activity (MaRIA), and depending on its values patients were categorized as high or low activity. Additionally, the presence of creeping fat (CrF) was used to evaluate activity. ADC and PMI were using Student's <i>t</i>-test.</p><p><strong>Results: </strong>Our study included 47 males and 41 females (mean age of 38.69 ±14.4 years). The ADC in uncomplicated (B1, <i>n</i> = 45) and complicated disease (B2 + B3, <i>n</i> = 43) were 1.11 ±0.19 and 1.03 ±0.10 (10<sup>-3</sup>*mm<sup>2</sup>/s), respectively, (<i>p</i> = 0.02). ADC was significantly lower in patients with stricturing disease than in patients without strictures (1.02 ±0.11 and 1.10 ±0.18 [10<sup>-3</sup> mm<sup>2</sup>/s], respectively, <i>p</i> = 0.01). The group with non-penetrating disease showed higher PMI than those with penetrating disease (5.71 ±1.88 vs. 4.42 ±1.55 cm<sup>2</sup>/m<sup>2</sup>, respectively, <i>p</i> = 0.10). There was no significant difference in PMI and ADC between patients with low and high MaRIA or positive and negative CrF.</p><p><strong>Conclusions: </strong>The ADC of the psoas muscles is significantly lower in CD patients with uncomplicated disease, particularly those with stricturing disease. Therefore, ADC can be considered as an imaging biomarker of myopathic changes in CD patients.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 1","pages":"74-80"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140866465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunohistochemical detection of MnSOD in colon adenocarcinoma patients - clinical application. 结肠腺癌患者 MnSOD 的免疫组化检测--临床应用。
IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-04-26 DOI: 10.5114/pg.2024.139238
Jerzy Z Piecuch, Marek Kucharzewski, Grzegorz Wyrobiec, Marlena Brzozowa-Zasada

Introduction: Colon adenocarcinoma (COAD) is one of the most frequently identified cancers of the digestive system. It is worth noting that the 5-year survival rates for patients diagnosed early are approximately 90%, whereas for patients with advanced diagnosis it is only 10%. It may indicate that metastasis is a critical cause of death for cancer patients.

Aim: The current study investigated the immunohistochemical expression of MnSOD in individuals living in Poland, who were diagnosed as colon adenocarcinoma patients, to assess its prognostic significance by correlating its expression with the clinicopathological factors and overall survival (OS).

Material and methods: Paraffin-embedded adenocarcinoma samples were assessed immunohistochemically for MnSOD protein. The relationship between MnSOD immunoexpression and clinicopathological factors including the 5-year overall survival (OS) were evaluated.

Results: Immunohistochemical expression of MnSOD protein was detected in colon adenocarcinoma samples and non-pathological samples of colon tissues. As demonstrated, the level of the MnSOD immunohistochemical reactivity was not correlated with clinicopathological factors. A multivariate analysis demonstrated that the grade of tumour differentiation and MnSOD immunoexpression in healthy tissues were independent risk factors for worse survival of patients.

Conclusions: The high level of MnSOD immunoexpression in cancerous tissue was not associated with malignancy-related clinicopathological factors and 5-year overall survival of patients.

简介结肠腺癌(COAD)是最常见的消化系统癌症之一。值得注意的是,早期诊断患者的 5 年生存率约为 90%,而晚期诊断患者的 5 年生存率仅为 10%。目的:本研究调查了波兰结肠腺癌患者 MnSOD 的免疫组化表达情况,通过将其表达与临床病理因素和总生存率(OS)相关联来评估其预后意义:对石蜡包埋的腺癌样本进行 MnSOD 蛋白免疫组化评估。评估了MnSOD免疫表达与临床病理因素(包括5年总生存率(OS))之间的关系:结果:结肠腺癌样本和非病理结肠组织样本中都检测到了 MnSOD 蛋白的免疫组化表达。结果表明,MnSOD 免疫组化反应水平与临床病理因素无关。多变量分析表明,肿瘤分化等级和健康组织中的 MnSOD 免疫表达是导致患者生存率降低的独立风险因素:结论:癌症组织中高水平的MnSOD免疫表达与恶性肿瘤相关的临床病理因素和患者的5年总生存率无关。
{"title":"Immunohistochemical detection of MnSOD in colon adenocarcinoma patients - clinical application.","authors":"Jerzy Z Piecuch, Marek Kucharzewski, Grzegorz Wyrobiec, Marlena Brzozowa-Zasada","doi":"10.5114/pg.2024.139238","DOIUrl":"https://doi.org/10.5114/pg.2024.139238","url":null,"abstract":"<p><strong>Introduction: </strong>Colon adenocarcinoma (COAD) is one of the most frequently identified cancers of the digestive system. It is worth noting that the 5-year survival rates for patients diagnosed early are approximately 90%, whereas for patients with advanced diagnosis it is only 10%. It may indicate that metastasis is a critical cause of death for cancer patients.</p><p><strong>Aim: </strong>The current study investigated the immunohistochemical expression of MnSOD in individuals living in Poland, who were diagnosed as colon adenocarcinoma patients, to assess its prognostic significance by correlating its expression with the clinicopathological factors and overall survival (OS).</p><p><strong>Material and methods: </strong>Paraffin-embedded adenocarcinoma samples were assessed immunohistochemically for MnSOD protein. The relationship between MnSOD immunoexpression and clinicopathological factors including the 5-year overall survival (OS) were evaluated.</p><p><strong>Results: </strong>Immunohistochemical expression of MnSOD protein was detected in colon adenocarcinoma samples and non-pathological samples of colon tissues. As demonstrated, the level of the MnSOD immunohistochemical reactivity was not correlated with clinicopathological factors. A multivariate analysis demonstrated that the grade of tumour differentiation and MnSOD immunoexpression in healthy tissues were independent risk factors for worse survival of patients.</p><p><strong>Conclusions: </strong>The high level of MnSOD immunoexpression in cancerous tissue was not associated with malignancy-related clinicopathological factors and 5-year overall survival of patients.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"186-193"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consumption of proton pump inhibitors in outpatients of Gastroenterology Clinics in Khyber Pakhtunkhwa: evidence of inexpedient use. 开伯尔-普赫图赫瓦省胃肠病诊所门诊病人使用质子泵抑制剂的情况:不适当使用的证据。
IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-05-08 DOI: 10.5114/pg.2024.139429
Muhammad Ashfaq, Syed Mobasher Ali Abid, Qasim Khan, Muhammad Junaid Hassan Sharif, Muhammad Zeeshan Haroon, Adil Naseer Khan, Yasser Msa Alkahraman

Introduction: Proton pump inhibitors (PPIs) are effective drugs used for multiple gastrointestinal complications. They are commonly used in both hospitalised and outpatients. However, little is known about its utilisation pattern in ambulatory patients.

Aim: To evaluate the inexpedient continuous use of PPIs in patients with respect to treatment duration.

Material and methods: A cross-sectional observational study was conducted from January 2018 to November 2019 in Khyber Pakhtunkhwa, Pakistan. Regular proton pump inhibitor users were identified through patient histories.

Results: During the study period, 171 patients were included using a non-probability consecutive sampling technique, who were using regular proton pump inhibitors for a longer duration, i.e. from 3 months to 15 years. The highest proportion (42.8%) were using PPI regularly from 3 months to 1 year followed by 22.9% for 1-2 years, 12.0% for 2-3 years, 7.8% for 3-4 years, 4.2% for 4-5 years, and 10.24% for > 5 years. Omeprazole and esomeprazole were the most commonly used drugs, with 71.1% and 23.5% prevalence, respectively. A total of 33.73% of patients had continued PPI use on their own after initially being prescribed by the physician.

Conclusions: It can be deduced that PPIs are used in outpatients beyond standard treatment guidelines. The inexpedient continuous use of proton pump inhibitors is of concern due to the risk of developing adverse effects. Therefore, patient counselling and periodic monitoring must be carried out to prevent the irrational use of PPIs.

简介:质子泵抑制剂(PPI)是治疗多种胃肠道并发症的有效药物。无论是住院病人还是门诊病人都经常使用。然而,人们对其在非卧床患者中的使用模式却知之甚少。目的:评估患者在治疗持续时间方面非连续使用 PPIs 的情况:2018年1月至2019年11月,在巴基斯坦开伯尔巴图克瓦省开展了一项横断面观察研究。通过患者病史确定了质子泵抑制剂的定期使用者:在研究期间,采用非概率连续抽样技术纳入了 171 名患者,他们长期使用质子泵抑制剂,即从 3 个月到 15 年不等。定期使用质子泵抑制剂 3 个月至 1 年的患者比例最高(42.8%),其次是 1-2 年的 22.9%、2-3 年的 12.0%、3-4 年的 7.8%、4-5 年的 4.2%,以及超过 5 年的 10.24%。奥美拉唑和埃索美拉唑是最常用的药物,使用率分别为 71.1%和 23.5%。共有 33.73% 的患者在医生开具处方后自行继续使用 PPI:结论:可以推断出,门诊患者对 PPIs 的使用超出了标准治疗指南的范围。由于存在产生不良反应的风险,质子泵抑制剂的不当持续使用令人担忧。因此,必须对患者进行指导和定期监测,以防止不合理使用质子泵抑制剂。
{"title":"Consumption of proton pump inhibitors in outpatients of Gastroenterology Clinics in Khyber Pakhtunkhwa: evidence of inexpedient use.","authors":"Muhammad Ashfaq, Syed Mobasher Ali Abid, Qasim Khan, Muhammad Junaid Hassan Sharif, Muhammad Zeeshan Haroon, Adil Naseer Khan, Yasser Msa Alkahraman","doi":"10.5114/pg.2024.139429","DOIUrl":"https://doi.org/10.5114/pg.2024.139429","url":null,"abstract":"<p><strong>Introduction: </strong>Proton pump inhibitors (PPIs) are effective drugs used for multiple gastrointestinal complications. They are commonly used in both hospitalised and outpatients. However, little is known about its utilisation pattern in ambulatory patients.</p><p><strong>Aim: </strong>To evaluate the inexpedient continuous use of PPIs in patients with respect to treatment duration.</p><p><strong>Material and methods: </strong>A cross-sectional observational study was conducted from January 2018 to November 2019 in Khyber Pakhtunkhwa, Pakistan. Regular proton pump inhibitor users were identified through patient histories.</p><p><strong>Results: </strong>During the study period, 171 patients were included using a non-probability consecutive sampling technique, who were using regular proton pump inhibitors for a longer duration, i.e. from 3 months to 15 years. The highest proportion (42.8%) were using PPI regularly from 3 months to 1 year followed by 22.9% for 1-2 years, 12.0% for 2-3 years, 7.8% for 3-4 years, 4.2% for 4-5 years, and 10.24% for > 5 years. Omeprazole and esomeprazole were the most commonly used drugs, with 71.1% and 23.5% prevalence, respectively. A total of 33.73% of patients had continued PPI use on their own after initially being prescribed by the physician.</p><p><strong>Conclusions: </strong>It can be deduced that PPIs are used in outpatients beyond standard treatment guidelines. The inexpedient continuous use of proton pump inhibitors is of concern due to the risk of developing adverse effects. Therefore, patient counselling and periodic monitoring must be carried out to prevent the irrational use of PPIs.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"159-164"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevention of obesity and carbohydrate metabolism disorders in the population at an industrial facility. 预防工业设施人群的肥胖症和碳水化合物代谢紊乱。
IF 1.3 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-14 DOI: 10.5114/pg.2024.136246
Maxim Tszyan

Introduction: One of the urgent tasks of modern healthcare is the development of measures aimed at preventing obesity in the able-bodied population, including in the Republic of Kazakhstan, which would reduce economic losses and increase the coefficient of life expectancy in the population.

Aim: To identify measures for the early prevention of excess weight, obesity, and carbohydrate metabolism disorders in the able-bodied population at an industrial facility in Kazakhstan.

Material and methods: The study involved 662 people (574 men and 88 women) aged 19 to 64 years. The subjects were divided into 2 groups: the main group - persons with obesity (242 people) and the control group - relatively healthy persons (422 people). The diagnosis of obesity was made based on the medical history of a patient, external examination, and physical, laboratory, and instrumental assessment.

Results: Three main factors influencing the development of obesity have been identified: a significant level of inactivity; serum glucose; the presence of comorbidities. Other factors (gender and age, smoking) do not have a significant effect on the increase in the body mass index of persons working at an industrial facility.

Conclusions: Accordingly, a priority in the prevention of obesity is a healthy lifestyle, involving regular physical activity and a healthy balanced diet.

导言:现代医疗保健的紧迫任务之一是制定旨在预防包括哈萨克斯坦共和国在内的健全人口肥胖症的措施,这将减少经济损失并提高人口预期寿命系数。目的:确定哈萨克斯坦工业设施中健全人口早期预防超重、肥胖和碳水化合物代谢紊乱的措施:研究涉及 662 人(574 名男性和 88 名女性),年龄在 19 至 64 岁之间。研究对象分为两组:主要组--肥胖症患者(242 人)和对照组--相对健康的人(422 人)。肥胖症的诊断是根据患者的病史、外部检查以及身体、实验室和仪器评估做出的:结果:已确定影响肥胖发生的三个主要因素:明显的缺乏活动;血清葡萄糖;合并症的存在。其他因素(性别和年龄、吸烟)对在工业设施工作的人员体重指数的增加没有明显影响:因此,预防肥胖的首要任务是养成健康的生活方式,包括定期进行体育锻炼和健康均衡的饮食。
{"title":"Prevention of obesity and carbohydrate metabolism disorders in the population at an industrial facility.","authors":"Maxim Tszyan","doi":"10.5114/pg.2024.136246","DOIUrl":"https://doi.org/10.5114/pg.2024.136246","url":null,"abstract":"<p><strong>Introduction: </strong>One of the urgent tasks of modern healthcare is the development of measures aimed at preventing obesity in the able-bodied population, including in the Republic of Kazakhstan, which would reduce economic losses and increase the coefficient of life expectancy in the population.</p><p><strong>Aim: </strong>To identify measures for the early prevention of excess weight, obesity, and carbohydrate metabolism disorders in the able-bodied population at an industrial facility in Kazakhstan.</p><p><strong>Material and methods: </strong>The study involved 662 people (574 men and 88 women) aged 19 to 64 years. The subjects were divided into 2 groups: the main group - persons with obesity (242 people) and the control group - relatively healthy persons (422 people). The diagnosis of obesity was made based on the medical history of a patient, external examination, and physical, laboratory, and instrumental assessment.</p><p><strong>Results: </strong>Three main factors influencing the development of obesity have been identified: a significant level of inactivity; serum glucose; the presence of comorbidities. Other factors (gender and age, smoking) do not have a significant effect on the increase in the body mass index of persons working at an industrial facility.</p><p><strong>Conclusions: </strong>Accordingly, a priority in the prevention of obesity is a healthy lifestyle, involving regular physical activity and a healthy balanced diet.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 1","pages":"33-45"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140869140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrent tetany in a male patient with short bowel syndrome and Crohn's disease. 一名患有短肠综合征和克罗恩病的男性患者反复四肢抽搐。
IF 1.3 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2023-11-27 DOI: 10.5114/pg.2023.133222
Paweł Kurzelowski, Maciej Pluskiewicz, Aleksandra Pilśniak, Agnieszka Jarosińska, Michał Holecki
{"title":"Recurrent tetany in a male patient with short bowel syndrome and Crohn's disease.","authors":"Paweł Kurzelowski, Maciej Pluskiewicz, Aleksandra Pilśniak, Agnieszka Jarosińska, Michał Holecki","doi":"10.5114/pg.2023.133222","DOIUrl":"https://doi.org/10.5114/pg.2023.133222","url":null,"abstract":"","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 1","pages":"97-98"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resistance to death pathway induction as a potential targeted therapy in CRISPR/Cas-9 knock-out colorectal cancer cell lines. 在 CRISPR/Cas-9 基因敲除的结直肠癌细胞系中,死亡通路诱导作为一种潜在的靶向疗法具有抗药性。
IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-02-05 DOI: 10.5114/pg.2024.134872
Malgorzata Adamiec-Organisciok, Magdalena Wegrzyn, Lukasz Cienciala, Ngoni Magate, Magdalena Skonieczna, Joanna Nackiewicz

Regulated cell death is a fundamental biological process that plays a crucial role in maintaining tissue homeostasis and eliminating damaged or unnecessary cells. Ferroptosis is an iron-dependent process, characterized by the accumulation of oxidized and damaged lipids, which leads to programmed cell death. Among the ferroptotic pathway genes regulating this process, GPX4, TFRC, ACSL4, FSP1, SLC7A11, and PROM2 could be considered. There are many well-known ferroptotic pathway regulators, which are discussed in this compact review. Cells with tissues of different origin display sensitive or resistant phenotypes to such regulators. In some cases, unexpected changes during cell treatment occurred, suggesting the possibility of regulating the death pathway. We assumed that possible changing of ferro-sensitivity to ferro-resistance in cells, especially in colorectal cancer cell lines, is responded for induced chemoresistance. Using novel techniques, such as CRISPR/Cas-9 genome editing, an induced phenotype "switching" is possible.

调节细胞死亡是一个基本的生物过程,在维持组织平衡和清除受损或不必要的细胞方面发挥着至关重要的作用。铁变态反应是一个依赖铁的过程,其特点是氧化和受损脂质的积累,从而导致细胞的程序性死亡。在调控这一过程的铁氧化途径基因中,GPX4、TFRC、ACSL4、FSP1、SLC7A11 和 PROM2 可被考虑在内。本综述将讨论许多众所周知的铁氧化途径调控因子。不同来源组织的细胞对这些调节因子表现出敏感或抵抗的表型。在某些情况下,细胞处理过程中出现了意想不到的变化,这表明死亡途径可能受到调控。我们认为,细胞(尤其是结直肠癌细胞株)对铁的敏感性可能转变为对铁的耐受性,这是诱导化疗耐药性的原因。利用 CRISPR/Cas-9 基因组编辑等新技术,诱导表型 "转换 "是可能的。
{"title":"Resistance to death pathway induction as a potential targeted therapy in CRISPR/Cas-9 knock-out colorectal cancer cell lines.","authors":"Malgorzata Adamiec-Organisciok, Magdalena Wegrzyn, Lukasz Cienciala, Ngoni Magate, Magdalena Skonieczna, Joanna Nackiewicz","doi":"10.5114/pg.2024.134872","DOIUrl":"https://doi.org/10.5114/pg.2024.134872","url":null,"abstract":"<p><p>Regulated cell death is a fundamental biological process that plays a crucial role in maintaining tissue homeostasis and eliminating damaged or unnecessary cells. Ferroptosis is an iron-dependent process, characterized by the accumulation of oxidized and damaged lipids, which leads to programmed cell death. Among the ferroptotic pathway genes regulating this process, GPX4, TFRC, ACSL4, FSP1, SLC7A11, and PROM2 could be considered. There are many well-known ferroptotic pathway regulators, which are discussed in this compact review. Cells with tissues of different origin display sensitive or resistant phenotypes to such regulators. In some cases, unexpected changes during cell treatment occurred, suggesting the possibility of regulating the death pathway. We assumed that possible changing of ferro-sensitivity to ferro-resistance in cells, especially in colorectal cancer cell lines, is responded for induced chemoresistance. Using novel techniques, such as CRISPR/Cas-9 genome editing, an induced phenotype \"switching\" is possible.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"112-120"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of ASF1B as a prognostic marker for liver cancer by meta-analysis and its immune value revealed by a comprehensive pan-cancer analysis of 33 human cancersrevealed by a comprehensive pan-cancer analysis of 33 human cancers 通过荟萃分析鉴定ASF1B作为肝癌预后标志物,并通过对33例人类癌症的综合泛癌分析揭示其免疫价值
IF 1.3 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-23 DOI: 10.5114/pg.2023.124423
Yiyang Chen, Wanbang Zhou, Yiju Gong, Xi Ou
Introduction As one of the most common malignant tumours, liver cancer is difficult to detect in the early stage, with strong metastasis and poor prognosis. Anti-silencing function protein 1 was originally discovered in yeast as a histone H3-H4 chaperone, and studies have shown that ASF1B may be a target for inhibiting the growth of hepatocellular carcinoma cells. Aim To evaluate the diagnostic and prognostic significance of ASF1B expression in human LIHC on the basis of TCGA data. Material and methods A meta-analysis revealed that high ASF1B expression was strongly associated with better overall survival. A comprehensive pan-cancer analysis of 33 human cancers revealed the immunotherapeutic value of ASF1B. Results In this study, we observed a significant upregulation of ASF1B expression in LIHC samples compared to non-cancer samples. Clinical analysis showed that high expression of ASF1B was associated with age, tumour status, and clinical stage. Survival analysis showed that patients with high ASF1B expression had worse overall survival and progression-free survival than patients with low ASF1B expression. The AUCs of the 1-year, 3-year, and 5-year survival-related ROC curves were 0.672, 0.590, and 0.591, respectively. Conclusions Our study shows that ASF1B may provide new ideas for the diagnosis and prognosis of liver cancer patients, as well as providing a new direction for the application of ASF1B in tumour immunotherapy.
{"title":"Identification of ASF1B as a prognostic marker for liver cancer by meta-analysis and its immune value revealed by a comprehensive pan-cancer analysis of 33 human cancersrevealed by a comprehensive pan-cancer analysis of 33 human cancers","authors":"Yiyang Chen, Wanbang Zhou, Yiju Gong, Xi Ou","doi":"10.5114/pg.2023.124423","DOIUrl":"https://doi.org/10.5114/pg.2023.124423","url":null,"abstract":"Introduction As one of the most common malignant tumours, liver cancer is difficult to detect in the early stage, with strong metastasis and poor prognosis. Anti-silencing function protein 1 was originally discovered in yeast as a histone H3-H4 chaperone, and studies have shown that ASF1B may be a target for inhibiting the growth of hepatocellular carcinoma cells. Aim To evaluate the diagnostic and prognostic significance of ASF1B expression in human LIHC on the basis of TCGA data. Material and methods A meta-analysis revealed that high ASF1B expression was strongly associated with better overall survival. A comprehensive pan-cancer analysis of 33 human cancers revealed the immunotherapeutic value of ASF1B. Results In this study, we observed a significant upregulation of ASF1B expression in LIHC samples compared to non-cancer samples. Clinical analysis showed that high expression of ASF1B was associated with age, tumour status, and clinical stage. Survival analysis showed that patients with high ASF1B expression had worse overall survival and progression-free survival than patients with low ASF1B expression. The AUCs of the 1-year, 3-year, and 5-year survival-related ROC curves were 0.672, 0.590, and 0.591, respectively. Conclusions Our study shows that ASF1B may provide new ideas for the diagnosis and prognosis of liver cancer patients, as well as providing a new direction for the application of ASF1B in tumour immunotherapy.","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"6 1","pages":"249 - 265"},"PeriodicalIF":1.3,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70475058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics of the endoscopic procedures performed in a hybrid tertiary-level hospital during the first year of the COVID-19 pandemic. COVID-19大流行第一年在三级混合医院进行的内窥镜手术的特点
IF 1.3 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-01-01 DOI: 10.5114/pg.2022.118136
Héctor Adrián Díaz Hernández, José Elihú Cuevas Castillejos, Godolfino Miranda Zazueta, Adriana Fabiola Romano Munive, Francisco Valdovinos Andraca

Introduction: The COVID-19 pandemic caused many changes in gastrointestinal endoscopy units.

Aim: To describe the changes that occurred in a gastrointestinal endoscopy unit of a hybrid hospital during the COVID-19 pandemic.

Material and methods: We performed a retrospective study of endoscopies performed in the first year of the COVID-19 pandemic. We collected and described the data of interest to the study, which is presented with numbers and percentages or measures of central tendency and dispersion as appropriate. Fisher's exact test or the χ2 test were used as appropriate.

Results: A total of 507 procedures were performed. There was a 92.5% reduction in the performance of endoscopic procedures. In all, 77 (15%) procedures were performed on patients with COVID-19. The most frequent procedures were esophagogastroduodenoscopy (EGD), colonoscopy, and endoscopic retrograde cholangiopancreatography (ERCP). The main indications were gastrointestinal bleeding, placement of enteral accesses, and alterations in the biliary and pancreatic ducts. Of these, 37 (48%) were therapeutic. Patients with COVID-19 were more susceptible to the development of complications.

Conclusions: During the first year of the COVID-19 pandemic, the number of endoscopic procedures performed decreased significantly. The procedures most often required were EGD, colonoscopy, and ERCP, mainly indicated by gastrointestinal bleeding, placement of enteral accesses, and alterations of the bile and pancreatic ducts.

新冠肺炎大流行导致胃肠道内窥镜检查单位发生了许多变化。目的:描述2019冠状病毒病大流行期间混合医院胃肠内窥镜病房发生的变化。材料和方法:我们对COVID-19大流行第一年进行的内窥镜检查进行了回顾性研究。我们收集并描述了对研究感兴趣的数据,这些数据以适当的数字和百分比或集中趋势和分散的度量来呈现。适当使用Fisher精确检验或χ2检验。结果:共手术507例。内窥镜手术的效果降低了92.5%。总共有77例(15%)对COVID-19患者进行了手术。最常见的手术是食管胃十二指肠镜检查(EGD)、结肠镜检查和内窥镜逆行胆管造影(ERCP)。主要适应症为消化道出血,肠内通路的放置,胆管和胰管的改变。其中37例(48%)是治疗性的。COVID-19患者更容易出现并发症。结论:在2019冠状病毒病大流行的第一年,内窥镜手术的数量显著减少。最常需要的程序是EGD,结肠镜检查和ERCP,主要指胃肠道出血,肠内通路的放置,以及胆管和胰管的改变。
{"title":"Characteristics of the endoscopic procedures performed in a hybrid tertiary-level hospital during the first year of the COVID-19 pandemic.","authors":"Héctor Adrián Díaz Hernández,&nbsp;José Elihú Cuevas Castillejos,&nbsp;Godolfino Miranda Zazueta,&nbsp;Adriana Fabiola Romano Munive,&nbsp;Francisco Valdovinos Andraca","doi":"10.5114/pg.2022.118136","DOIUrl":"https://doi.org/10.5114/pg.2022.118136","url":null,"abstract":"<p><strong>Introduction: </strong>The COVID-19 pandemic caused many changes in gastrointestinal endoscopy units.</p><p><strong>Aim: </strong>To describe the changes that occurred in a gastrointestinal endoscopy unit of a hybrid hospital during the COVID-19 pandemic.</p><p><strong>Material and methods: </strong>We performed a retrospective study of endoscopies performed in the first year of the COVID-19 pandemic. We collected and described the data of interest to the study, which is presented with numbers and percentages or measures of central tendency and dispersion as appropriate. Fisher's exact test or the χ<sup>2</sup> test were used as appropriate.</p><p><strong>Results: </strong>A total of 507 procedures were performed. There was a 92.5% reduction in the performance of endoscopic procedures. In all, 77 (15%) procedures were performed on patients with COVID-19. The most frequent procedures were esophagogastroduodenoscopy (EGD), colonoscopy, and endoscopic retrograde cholangiopancreatography (ERCP). The main indications were gastrointestinal bleeding, placement of enteral accesses, and alterations in the biliary and pancreatic ducts. Of these, 37 (48%) were therapeutic. Patients with COVID-19 were more susceptible to the development of complications.</p><p><strong>Conclusions: </strong>During the first year of the COVID-19 pandemic, the number of endoscopic procedures performed decreased significantly. The procedures most often required were EGD, colonoscopy, and ERCP, mainly indicated by gastrointestinal bleeding, placement of enteral accesses, and alterations of the bile and pancreatic ducts.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"18 2","pages":"198-203"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dd/09/PG-18-47490.PMC10395057.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9935790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Przegla̜d Gastroenterologiczny
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1